Align Technology (ALGN) Market Valuation Rose While Red Alder Boosted by $1.48 Million Its Holding; Celgene (CELG) Position Lifted by Korea Investment Corp

June 13, 2018 - By Richard Conner

Celgene Corporation (NASDAQ:CELG) Logo

Red Alder Llc increased its stake in Align Technology Inc (ALGN) by 277.18% based on its latest 2018Q1 regulatory filing with the SEC. Red Alder Llc bought 5,879 shares as the company’s stock rose 19.49% while stock markets declined. The hedge fund held 8,000 shares of the health care company at the end of 2018Q1, valued at $2.01M, up from 2,121 at the end of the previous reported quarter. Red Alder Llc who had been investing in Align Technology Inc for a number of months, seems to be bullish on the $28.39 billion market cap company. The stock increased 1.67% or $5.81 during the last trading session, reaching $354.25. About 817,546 shares traded. Align Technology, Inc. (NASDAQ:ALGN) has risen 125.29% since June 13, 2017 and is uptrending. It has outperformed by 112.72% the S&P500. Some Historical ALGN News: 25/04/2018 – ALGN REPORTS CHINA FDA OK FOR ITERO ELEMENT INTRAORAL SCANNER; 25/04/2018 – Align Technology 1Q Net $95.9M; 06/03/2018 – Align Technology to Host Investor Day on May 23, 2018; 25/04/2018 – ALIGN TECHNOLOGY – DISPUTE DOES NOT IMPACT CO’S EXISTING SUPPLY AGREEMENT WITH SDC WHICH REMAINS IN PLACE THROUGH 2019; 26/04/2018 – ALIGN TECHNOLOGY INC ALGN.O : BARCLAYS RAISES TARGET PRICE BY 2 PCT TO $295; 15/05/2018 – Sands Capital Management Buys 3.4% Position in Align Technology; 07/03/2018 – UNITEDHEALTH GROUP UNH.N , DIPLOMAT PHARMACY DPLO.N , CIGNA Cl.N , ANTHEM ANTM.N , ALIGN TECHNOLOGY ALGN.O : BARCLAYS STARTS WITH OVERWEIGHT RATING; 25/04/2018 – Align Technology Announces China Food and Drug Administration Approval for the iTero Element lntraoral Scanner; 23/05/2018 – Align Technology Hosts 2018 Investor Day; 04/04/2018 – Align Technology: Invisalign First Increases Applicability to 70 % of Annual Orthodontic Case Starts Worldwide

Korea Investment Corp increased its stake in Celgene Corp (CELG) by 1.63% based on its latest 2018Q1 regulatory filing with the SEC. Korea Investment Corp bought 10,681 shares as the company’s stock declined 18.51% with the market. The institutional investor held 664,446 shares of the major pharmaceuticals company at the end of 2018Q1, valued at $59.28M, up from 653,765 at the end of the previous reported quarter. Korea Investment Corp who had been investing in Celgene Corp for a number of months, seems to be bullish on the $56.15B market cap company. The stock decreased 1.10% or $0.86 during the last trading session, reaching $77.47. About 5.84M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since June 13, 2017 and is downtrending. It has underperformed by 45.22% the S&P500. Some Historical CELG News: 02/04/2018 – Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA┬« (Pembrolizumab) Combination Trials; 13/04/2018 – Opdivo (nivolumab), First PD-1 Inhibitor to Demonstrate Superior Survival Benefit Compared with Chemotherapy in a Predominantly; 10/04/2018 – NOVARTIS’S AFINITOR GETS FDA OK FOR TSC PARTIAL-ONSET SEIZURES; 16/03/2018 – GERMANY’S GBA SEES NO ADDED BENEFIT FOR NOVARTIS’S KISQALI; 24/04/2018 – Street View: Prothena’s early pipeline assets now in focus; 15/05/2018 – Rexahn Phase 2a Combination Study of RX-3117 and Abraxane in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage; 23/05/2018 – MERCK & CO’S KEYTRUDA SIGNIFICANTLY IMPROVED OVERALL SURVIVAL; 06/03/2018 – CELGENE COMPLETES PURCHASE OF JUNO THERAPEUTICS; 25/05/2018 – Oncolytics Biotech Collaborates With USC Using Pelareorep in Combination With Keytruda, Velcade and Dexamethasone to Treat Multiple Myeloma; 10/04/2018 – Celgene at Deutsche Bank Health Care Conference May 8

Korea Investment Corp, which manages about $21.49B US Long portfolio, decreased its stake in S&P Global Inc by 33,223 shares to 288,186 shares, valued at $55.06 million in 2018Q1, according to the filing. It also reduced its holding in Steel Dynamics Inc (NASDAQ:STLD) by 329,095 shares in the quarter, leaving it with 790,705 shares, and cut its stake in Exxon Mobil Corp (NYSE:XOM).

Since February 8, 2018, it had 2 insider purchases, and 5 sales for $5.91 million activity. CASEY MICHAEL D sold $1.02M worth of Celgene Corporation (NASDAQ:CELG) on Thursday, June 7. On Monday, March 12 LOUGHLIN JAMES J sold $851,093 worth of Celgene Corporation (NASDAQ:CELG) or 9,250 shares. KAPLAN GILLA had sold 18,500 shares worth $1.77M. MARIO ERNEST sold 13,370 shares worth $1.26M.

Investors sentiment decreased to 0.79 in 2018 Q1. Its down 0.04, from 0.83 in 2017Q4. It fall, as 120 investors sold CELG shares while 470 reduced holdings. 106 funds opened positions while 363 raised stakes. 513.18 million shares or 8.59% less from 561.38 million shares in 2017Q4 were reported. Davidson Investment Advsrs holds 0.98% or 102,392 shares. Cetera Advsr Limited Liability Com holds 5,321 shares or 0.03% of its portfolio. Amf Pensionsforsakring holds 873,550 shares. Ashfield Prtnrs Ltd Liability Corp invested 0.58% in Celgene Corporation (NASDAQ:CELG). First Personal Financial Serv holds 2,236 shares or 0.04% of its portfolio. First Republic Investment Mgmt Inc holds 0.33% or 463,814 shares in its portfolio. Hudock Grp Ltd Limited Liability Company owns 180 shares. Ls Invest Ltd Com invested 0.1% of its portfolio in Celgene Corporation (NASDAQ:CELG). Captrust Financial Advsrs invested in 8,119 shares or 0.04% of the stock. Ima Wealth Inc holds 1.09% or 27,350 shares in its portfolio. City, West Virginia-based fund reported 2,238 shares. Montecito Bancorp Trust accumulated 3,925 shares or 0.11% of the stock. The Delaware-based Riverhead Capital Ltd Liability Corporation has invested 0.08% in Celgene Corporation (NASDAQ:CELG). Inv Advsr Lc holds 2,802 shares. Thomas J Herzfeld Advisors Inc reported 300 shares or 0.01% of all its holdings.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Seekingalpha.com which released: “My 2 Cents On The Ozanimod Saga” on May 15, 2018, also Seekingalpha.com with their article: “Celgene: Still (Looks) Appealing” published on May 21, 2018, Seekingalpha.com published: “Will ‘Public Shaming’ Sink Celgene?” on May 21, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “Acceleron: Luspatercept New Data Is A Buy Signal” published on June 07, 2018 as well as 247Wallst.com‘s news article titled: “Short Sellers Up the Ante For Major Biotechs” with publication date: June 12, 2018.

Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 20 have Buy rating, 1 Sell and 14 Hold. Therefore 57% are positive. Celgene Corporation has $190 highest and $83 lowest target. $127.48’s average target is 64.55% above currents $77.47 stock price. Celgene Corporation had 150 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer on Monday, October 30 with “Outperform”. The stock of Celgene Corporation (NASDAQ:CELG) earned “Hold” rating by Wells Fargo on Thursday, October 26. BTIG Research downgraded the stock to “Neutral” rating in Wednesday, June 1 report. The stock has “Buy” rating by Stifel Nicolaus on Thursday, September 7. Citigroup maintained the stock with “Buy” rating in Thursday, September 29 report. On Thursday, December 21 the stock rating was maintained by Guggenheim with “Buy”. The company was maintained on Wednesday, October 5 by Jefferies. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, July 27. As per Sunday, August 13, the company rating was maintained by Jefferies. On Tuesday, April 19 the stock rating was maintained by Credit Suisse with “Outperform”.

More notable recent Align Technology, Inc. (NASDAQ:ALGN) news were published by: Investorplace.com which released: “The Top 20 Stocks of 2018” on June 12, 2018, also Seekingalpha.com with their article: “Best And Worst Performing Nasdaq 100 Stocks Of 2018” published on May 25, 2018, Nasdaq.com published: “Align Technology Global Funding Awarded Towards Advancing Orthodontic and Dental Research” on June 04, 2018. More interesting news about Align Technology, Inc. (NASDAQ:ALGN) were released by: Globenewswire.com and their article: “Align Technology to Speak at Upcoming Financial Conferences” published on June 06, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 17, 2018.

Investors sentiment decreased to 0.86 in 2018 Q1. Its down 0.07, from 0.93 in 2017Q4. It worsened, as 41 investors sold ALGN shares while 216 reduced holdings. 77 funds opened positions while 143 raised stakes. 60.14 million shares or 1.24% less from 60.90 million shares in 2017Q4 were reported. 3,000 are held by Eulav Asset Mngmt. Fdx Advsr reported 8,282 shares. Connor Clark And Lunn Invest stated it has 4,050 shares. Artisan Prtn Partnership accumulated 287,830 shares or 0.15% of the stock. Ithaka Grp Incorporated Limited Liability reported 47,041 shares. Norinchukin Bankshares The owns 6,610 shares. Bbva Compass Bank Inc holds 2,686 shares. Disciplined Growth Invsts Mn holds 4.74% or 959,365 shares in its portfolio. Atlantic Group Inc Llc holds 416,325 shares. Matarin Capital Mgmt Limited Company reported 0% stake. Sit Investment accumulated 0.12% or 18,685 shares. Envestnet Asset Management Incorporated owns 30,258 shares. Waddell Reed Fincl reported 58,000 shares stake. Advantus Mgmt Inc holds 7,486 shares. Bluemountain Cap Lc invested in 14,666 shares or 0.08% of the stock.

Among 17 analysts covering Align Technology (NASDAQ:ALGN), 14 have Buy rating, 0 Sell and 3 Hold. Therefore 82% are positive. Align Technology had 69 analyst reports since July 27, 2015 according to SRatingsIntel. Barclays Capital maintained the shares of ALGN in report on Monday, May 21 with “Overweight” rating. The stock has “Equal-Weight” rating by Morgan Stanley on Thursday, April 19. The firm earned “Buy” rating on Thursday, November 9 by Credit Suisse. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, November 21. As per Friday, January 29, the company rating was maintained by Stifel Nicolaus. The company was maintained on Tuesday, May 22 by Stifel Nicolaus. On Wednesday, January 31 the stock rating was maintained by Piper Jaffray with “Buy”. Stifel Nicolaus maintained Align Technology, Inc. (NASDAQ:ALGN) rating on Tuesday, October 17. Stifel Nicolaus has “Buy” rating and $205.0 target. The rating was maintained by Morgan Stanley with “Overweight” on Monday, July 17. The company was maintained on Thursday, May 24 by PiperJaffray.

Since February 2, 2018, it had 2 insider buys, and 15 selling transactions for $61.37 million activity. SANTORA GREG J sold 5,500 shares worth $1.78M. Shares for $1.11 million were bought by GEORGE ROGER E. Shares for $1.37 million were sold by Hockridge Stuart A on Thursday, May 24. $11.91M worth of Align Technology, Inc. (NASDAQ:ALGN) shares were sold by Wright Emory. PRESCOTT THOMAS M also sold $20.73M worth of Align Technology, Inc. (NASDAQ:ALGN) on Monday, April 30. $5.79M worth of Align Technology, Inc. (NASDAQ:ALGN) shares were sold by LACOB JOSEPH.

Align Technology, Inc. (NASDAQ:ALGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: